PGP and cancer: Considering that the use of chemotherapeutic agents for patients with cancer is strongly correlated with a higher incidence of recurrence of drug-resistant cancer due to P-gp overexpression (4, 5, 7), our findings may also contribute to the selection of crizotinib for the prevention or reduction of the incidence of drug-resistant cancer in early therapy for patients with cancer.